Business
Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)
Preclinical data demonstrate potential efficacy and safety of OV329 at low, chronic dosing, suggesting an improved profile compared to other
About this update from Ovid Therapeutics Inc.
[{"type":"text","content":"Preclinical data demonstrate potential efficacy and safety of OV329 at low, chronic dosing, suggesting an improved profile compared to other GABA-aminotransferase inhibitors Data from the NIH/NINDs Epilepsy Therapy Screening Program demonstrate that OV329 confers protection from seizure activity in several treatment-resistant animal models New preclinical data on OV350 underscore the potential of activating the KCC2 to alleviate refractory status epilepticus and limit neuronal damage NEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, today announced that preclinical data supporting its OV329 and OV350 programs in epilepsy and treatment-resistant seizures will be presented at the 2022 American Epilepsy Society (AES) Annual Meeting, taking place December 2-6 in Nashville, Tennessee. “We are excited to return to AES with encouraging preclinical data supporting the anti-seizure potential of what we anticipate will be a first-in-class KCC2 program and best-in-class program for GABA-aminotransferase inhibitors. If successful, these programs will provide hope for people with treatment-resistant epilepsies,” said Jeremy Levin, D. Phil, MB BChir and Chairman and Chief Executive Officer of Ovid Therapeutics. “Our pipeline of potential medicines is designed with unique mechanisms of action to address the diverse, underlying pathophysiology of seizures. Our data suggest OV329 to be a potent, next-generation GABA-AT inhibitor with the potential for seizure reduction with chronic, low dosing. Data presented on OV350 support the therapeutic opportunity associated with activating KCC2, a novel target in epilepsy.” Posters to be presented on Ovid development programs are listed here: Title: Evaluation of OV329, a next-generation GABA-AT inhibitor in a series of pharmaco-resistant seizure models through the NINDS Epilepsy Therapy Screening ProgramSession Date & Time: 12-2 p.m. CST, Sunday, December 4 Presenter: Patrick Sarmiere, Ph.D.Poster Number: #2.215 Summary: Using the NIH/NINDS Epilepsy Therapy Screening Program (ETSP), a series of signal-finding studies using multiple mouse seizure models, found that OV329 demonstrated efficacy in the subacute models of epi...